2024-08-02 09:16:28
Starting from the 1st of this month, the 292 won insurance benefit will be applied to each party.
Response to low-dose demand for elderly patients and increase in prescription options
Recently, we started producing the Idalbi series ourselves.
“ARB series proven to have excellent blood pressure lowering effect”
Celltrion Pharmaceuticals announced on the 1st that its hypertension treatment drug ‘Idalbijeong (ingredient name: Azilsartan Medoxomil) 20mg’ has entered the domestic sales process after passing the insurance price notification.
Idalbijeong 20mg received product approval from the Ministry of Food and Drug Safety in May, and was covered by health insurance at 292 won per tablet starting from the 1st of this month in accordance with the Ministry of Health and Welfare’s notice on the upper limit of pharmaceutical benefits.
Celltrion expects that the convenience and preference of prescriptions will improve as the range of customized prescriptions according to patient conditions has been expanded by adding a low-dose item of 20 mg in addition to the existing 40 and 80 mg of Idalbi. In particular, it is expected that the convenience will increase for the very elderly (75 years of age or older) and patients with special diseases who require initial low-dose prescriptions.
Idalbi is an original hypertension treatment drug in the angiotensin II receptor blocker (ARB) series. It has a mechanism of lowering blood pressure by blocking the receptor of the hormone angiotensin II, which increases blood pressure, and expanding blood vessels. The results of a phase 3 clinical trial targeting stage 1-2 hypertension patients demonstrated a superior 24-hour blood pressure lowering effect compared to other ARB series ingredients. In terms of safety, it also showed similar results to the control group and placebo.
In addition to Idarbi, which is expanding its influence in the market, Celltrion Pharmaceuticals is also supplying ‘Idarbiclo’, a combination drug that adds the thiazide diuretic chlorthalidone to the main ingredient of Idarbi. With this product expansion, it is expected to build a solid product portfolio that includes combination drugs, thereby significantly strengthening its position in the market.
A Celltrion official said, “With the domestic launch of the 20mg Idalbi tablet, we will be able to increase patient convenience and expand the range of prescription options for medical professionals,” adding, “We will do our best to contribute to improving the quality of life of domestic hypertensive patients through the production and supply of high-quality pharmaceutical products.”
Meanwhile, Celltrion Pharmaceuticals recently completed the internalization of production of Idalbi and Idalbiclo, which were previously supplied from external production facilities, and began full-scale in-house production. It is expected that this will contribute to improved performance and more stable market supply as logistics costs and production costs can be reduced compared to external supply.
Kim Min-beom, Donga.com reporter [email protected]
-
- great
- 0dog
-
- I’m so sad
- 0dog
-
- I’m angry
- 0dog
-
- I recommend it
- dog
Hot news right now
2024-08-02 09:16:28